Top Markets
#1 Black Phoenix Black Phoenix +736.70%
#2 Beam Beam +35.79%
#3 SAFEcoin SAFEcoin +19.80%
#4 TENDIES TENDIES +17.80%
#5 THORChain THORChain +17.71%
#6 Tutorial Tutorial +16.47%
#7 EfficientFrontier EfficientFrontier +15.89%
#8 Bless Bless +14.32%
#9 THORChain Yield THORChain Yield +13.26%
#10 Versatize Coin Versatize Coin +12.50%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rangering i aksjer #5676
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Aksjekurs
$62.49
Sist synkronisert: 2024-03-06
Markedsverdi
$2.52B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel RayzeBio, Inc. Common Stock (RYZB)

Kategori

Healthcare
Inntekter for RayzeBio, Inc. Common Stock (RYZB)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til RayzeBio, Inc. Common Stock er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for RayzeBio, Inc. Common Stock fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH